

Supplementary Table 1**The sequence of primers for quantitative real-time PCR**

Gene name	Primer sequence forward (5'-3')
miR-7-5p	TGGAAGACTAGTGATTTTGTTGTT
miR-9-5p	TCTTTGGTTATCTAGCTGTATGA
miR-16-5p	TAGCAGCACGTAAATATTGGCG
miR-18a-5p	TAAGGTGCATCTAGTGCAGATAG
miR-20a-5p	TAAAGTGCTTATAGTGCAGGTAG
miR-21-5p	TAGCTTATCAGACTGATGTTGA
miR-29a-3p	TAGCACCATCTGAAATCGGTTA
miR-122-5p	TGGAGTGTGACAATGGTGTTTG
miR-142-3p	TGTAGTGTTTCCTACTTTATGGA
miR-144-3p	TACAGTATAGATGATGTACT
miR-146a-5p	TGAGAACTGAATTCCATGGGTT
miR-155-5p	TTAATGCTAATCGTGATAGGGGTT
miR-192-5p	CTGACCTATGAATTGACAGCC
miR-200a-5p	CATCTTACCGGACAGTGCTGGA
miR-210-3p	CTGTGCGTGTGACAGCGGCTGA
miR-221-3p	AGCTACATTGTCTGCTGGGTTTC
miR-375-3p	TTTGTTTCGTTCCGGCTCGCGTGA
miR-382-5p	GAAGTTGTTTCGTGGTGGATTCTG
miR-572	GTCCGCTCGGCGGTGGCCCA
miR-615-5p	GGGGGTCCCCGGTGCTCGGATC
U6 Forward	CTCGCTTCGGCAGCACA
U6 Reverse	AACGCTTCACGAATTTGCGTT

Supplementary Table 2: Differential expression of the selected miRNAs (Raw Cycle threshold values)

Participant ID	miR-7- 5p	miR-9-5p	miR-16-5p	miR-18a- 5p	miR-20a-5p	miR-21-5p	miR-29a- 3p	miR-122-5p	miR-142-3p	miR-144-3p	miR-146a- 5p	miR-155-5p	miR-192-5p	miR-200a- 5p	miR-210-3p	miR-221-3p	miR-375-3p	miR-382-5p	miR-572	miR-615-5p	u6
(a) ART-naive PLWH																					
NV-62	45.0	45.0	38.1	45.0	36.2	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	31.6	45.0	45.0	38.1
NV-63	45.0	32.3	38.7	45.0	36.2	45.0	45.0	45.0	45.0	32.7	45.0	45.0	45.0	45.0	45.0	45.0	45.0	32.2	45.0	11.9	36.6
NV-65	45.0	45.0	35.8	45.0	36.0	45.0	45.0	45.0	36.4	34.6	37.5	39.0	41.5	45.0	45.0	45.0	45.0	32.3	42.8	10.7	37.2
NV-66	45.0	34.3	35.0	45.0	45.0	45.0	45.0	45.0	45.0	32.6	38.3	39.6	45.0	43.1	45.0	42.4	45.0	32.7	45.0	45.0	35.6
NV-70	38.2	33.7	33.0	33.7	35.1	34.3	34.8	36.9	33.5	32.1	37.3	45.0	45.0	37.9	37.7	37.7	45.0	32.9	45.0	11.8	36.3
NV-71	37.3	31.6	31.6	45.0	34.4	32.1	35.6	37.0	34.0	45.0	36.7	39.5	37.1	35.5	41.3	37.2	37.1	33.2	45.0	11.5	38.7
NV-72	36.7	30.4	34.4	45.0	33.8	34.9	35.1	31.7	33.8	45.0	36.6	38.2	37.0	35.3	37.1	35.9	36.9	45.0	45.0	11.6	37.5
NV-75	37.6	34.1	33.5	40.5	45.0	32.2	31.0	32.9	35.4	32.7	37.5	39.3	36.4	36.5	41.5	37.7	45.0	35.0	43.2	11.6	36.2
NV-76	38.7	38.3	37.4	38.9	35.4	32.2	35.2	33.5	45.0	33.0	45.0	39.0	41.2	33.3	41.5	37.1	39.0	33.8	45.0	11.4	39.4
NV-77	45.0	36.8	33.4	45.0	35.6	29.9	34.7	33.2	37.0	45.0	38.6	40.3	39.1	30.4	45.0	39.1	45.0	40.2	45.0	11.4	39.4
NV-78	45.0	41.7	28.9	45.0	36.3	33.7	35.2	40.0	36.1	45.0	45.0	41.2	37.7	28.8	45.0	38.8	45.0	39.7	45.0	11.8	38.2
NV-79	45.0	33.6	32.4	39.2	35.5	45.0	45.0	45.0	36.3	31.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	33.3	45.0	11.8	37.0
NV-80	45.0	45.0	34.2	45.0	35.0	34.8	36.8	40.4	37.5	45.0	45.0	37.3	36.9	35.6	45.0	36.9	45.0	41.6	45.0	12.9	38.9
NV-83	45.0	38.5	31.9	45.0	35.2	34.2	35.0	40.5	38.5	45.0	45.0	37.8	34.9	38.2	37.8	37.5	37.7	45.0	38.8	11.1	33.3
NV-86	45.0	36.1	31.0	45.0	42.6	45.0	45.0	45.0	38.8	45.0	45.0	39.3	45.0	45.0	45.0	45.0	45.0	45.0	43.1	12.9	34.1
NV-87	45.0	45.0	31.0	45.0	39.0	45.0	45.0	45.0	45.0	32.3	45.0	45.0	45.0	45.0	39.7	45.0	38.5	35.1	38.3	11.9	39.1
(b) ART-treated PLWH																					
SS-09	45.0	39.5	33.3	45.0	45.0	45.0	45.0	45.0	35.4	45.0	38.8	45.0	45.0	45.0	45.0	45.0	45.0	32.5	45.0	10.8	39.7
SS-10	41.6	45.0	33.9	45.0	45.0	45.0	45.0	45.0	40.4	45.0	45.0	45.0	45.0	43.2	45.0	45.0	45.0	33.5	45.0	11.6	36.7
SS-11	43.4	35.4	32.8	40.5	45.0	45.0	45.0	45.0	35.4	45.0	36.3	37.5	43.1	42.7	43.1	45.0	45.0	33.1	41.5	11.1	37.2
SS-12	45.0	35.4	31.5	45.0	45.0	45.0	45.0	45.0	38.5	45.0	35.7	39.8	42.4	45.0	45.0	45.0	42.0	33.8	42.4	10.9	35.2
SS-14	45.0	35.6	32.1	39.8	41.0	43.1	45.0	45.0	45.0	45.0	18.5	39.6	42.8	41.7	42.0	40.7	31.7	31.4	38.0	10.5	37.0
SS-15	45.0	34.4	32.4	45.0	39.9	41.0	42.4	45.0	38.8	42.4	41.0	38.6	36.9	32.9	33.5	31.1	32.1	31.1	35.7	10.5	39.0
SS-16	45.0	33.0	32.6	34.7	32.2	31.7	36.2	35.0	33.0	43.1	35.7	39.1	34.6	31.6	31.5	31.0	30.1	31.3	32.3	10.6	36.7
SS-17	35.8	38.1	33.5	39.3	32.5	30.9	38.1	34.9	37.1	35.7	35.0	39.1	35.8	32.0	30.7	31.0	30.0	32.3	32.1	10.1	37.0
SS-18	36.7	40.1	34.7	39.1	32.4	31.5	36.0	36.1	40.7	40.4	39.1	42.4	36.0	33.3	31.6	31.7	30.8	35.4	32.6	10.1	38.5
SS-19	45.0	37.8	36.2	38.3	32.3	31.4	38.8	38.9	38.1	37.3	45.0	41.6	38.5	34.5	32.8	32.3	31.7	34.9	33.3	10.7	38.4
SS-20	35.9	37.6	36.7	40.0	33.4	30.5	37.1	36.5	36.4	35.0	36.4	45.0	37.6	33.2	32.2	31.6	31.1	33.8	33.6	10.7	38.2
SS-57	41.2	36.4	34.5	38.7	33.5	30.6	39.8	37.1	36.9	35.2	45.0	37.8	38.2	33.4	32.8	31.5	31.2	33.8	33.3	10.9	39.4
SS-59	38.0	36.6	34.8	45.0	34.4	31.2	45.0	35.8	36.6	34.0	45.0	40.0	35.7	32.2	32.2	31.7	30.5	32.9	32.5	10.9	37.8
SS-82	38.4	35.1	34.3	36.5	32.9	30.6	38.3	36.1	34.9	34.3	39.0	45.0	35.7	32.6	31.5	31.7	31.0	33.5	33.0	11.0	34.0
SS-83	45.0	41.6	36.8	45.0	39.1	41.3	42.5	38.0	40.4	41.1	41.7	45.0	36.6	35.5	35.5	35.1	35.3	42.0	39.1	45.0	35.1
SS-84	45.0	45.0	40.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	41.3	39.8	45.0	39.2	35.8	34.7	33.2	41.0	35.4	45.0	39.2
SS-85	45.0	45.0	45.0	45.0	35.5	34.9	45.0	40.8	45.0	45.0	45.0	38.4	45.0	35.6	35.5	34.9	33.8	41.8	36.2	45.0	38.8
SS-86	45.0	45.0	45.0	45.0	35.8	34.8	45.0	39.6	45.0	45.0	40.7	37.2	36.6	39.1	38.5	33.6	29.3	45.0	33.3	45.0	34.3
SS-87	45.0	45.0	33.8	45.0	33.2	32.2	38.9	37.5	45.0	45.0	40.4	45.0	38.4	35.6	35.5	35.5	34.2	42.4	35.6	45.0	35.8
SS-88	37.6	38.5	34.0	45.0	33.5	31.6	37.6	37.9	45.0	45.0	45.0	38.3	36.6	31.7	32.0	31.6	30.4	34.4	32.1	11.4	36.7
SS-89	37.9	34.7	33.3	45.0	33.6	33.3	45.0	35.0	34.3	45.0	36.9	45.0	39.7	31.4	30.7	31.9	29.8	31.4	31.6	11.3	36.4
SS-90	35.1	33.4	32.5	45.0	32.6	31.7	35.3	34.4	34.0	45.0	36.9	37.7	35.1	30.5	30.8	31.2	29.8	31.5	31.3	11.3	39.3
SS-91	35.4	31.2	31.8	33.4	31.5	30.8	34.9	34.6	31.5	32.4	37.7	38.9	34.9	30.4	31.0	31.0	29.8	30.3	31.2	11.2	37.4
SS-92	37.4	32.2	31.7	39.9	35.0	31.1	35.4	34.3	45.0	45.0	34.8	45.0	35.4	30.2	30.3	30.5	29.2	29.5	31.1	11.4	37.1
SS-93	45.0	30.9	31.3	33.6	31.5	30.8	36.7	35.3	31.3	41.1	37.5	45.0	36.5	30.1	30.7	30.4	29.2	29.5	30.8	11.3	38.2
SS-94	45.0	31.3	32.2	42.0	31.8	31.2	34.1	34.1	31.6	32.6	37.5	45.0	35.0	30.5	30.8	30.3	29.7	30.2	31.2	11.5	36.3
SS-95	45.0	34.4	32.8	36.3	33.0	30.8	37.2	35.6	34.6	33.2	36.9	39.0	36.2	33.0	32.8	31.5	30.8	32.3	33.0	11.1	35.3
(c) Uninfected controls																					
AGK-P1	45.0	43.1	38.5	45.0	33.7	42.1	43.1	45.0	31.7	42.1	34.8	38.9	42.1	45.0	42.1	45.0	45.0	41.0	45.0	9.0	32.1
AGK-P2	45.0	45.0	37.0	41.9	30.8	33.8	45.0	41.9	28.9	40.1	33.4	37.1	40.1	45.0	40.1	45.0	36.2	32.6	37.7	9.0	32.6
AGK-P3	42.0	41.2	34.1	42.2	32.3	41.9	41.2	45.0	32.9	41.9	34.3	38.5	41.9	45.0	41.9	45.0	41.2	31.0	42.1	9.9	33.6
AGK-P4	42.3	41.4	29.2	37.7	32.3	42.0	41.4	40.9	28.9	42.0	32.5	38.3	42.0	45.0	42.0	45.0	42.5	33.1	41.8	10.2	32.4
AGK-P5	45.0	42.1	32.8	38.1	32.5	39.6	36.6	37.7	31.0	45.0	38.3	45.0	40.9	41.3	40.9	36.1	40.9	33.1	38.2	12.6	32.7
AGK-P6	42.2	40.2	30.7	45.0	32.7	38.2	39.6	41.8	31.5	45.0	36.2	45.0	39.4	39.1	41.0	34.7	41.0	33.3	37.8	11.1	31.7
AGK-P7	41.6	40.0	29.6	41.3	29.8	35.7	39.6	37.1	28.3	42.2	33.1	38.8	39.1	39.3	37.0	37.0	37.3	30.5	36.5	11.3	31.7
AGK-P8	42.2	35.7	29.3	40.2	29.0	34.1	34.1	36.8	27.5	35.1	31.0	38.8	35.6	39.8	37.9	33.0	37.8	32.8	39.1	11.5	31.7
AGK-P9	37.4	37.2	27.9	36.3	28.2	37.2	36.9	34.6	27.8	38.0	32.3	45.0	37.1	32.5	45.0	31.9	37.3	30.4	40.5	12.2	32.4
AGK-P10	42.7	41.2	27.3	42.1	31.0	33.0	35.6	34.4	29.0	33.1	31.6	37.0	32.3	35.3	38.0	30.2	41.7	33.2	37.3	12.4	32.2

Supplementary Table 3: Demographic and clinical characteristics of the 53 participants

Participant ID	Age (Years)	Sex	Viral load (copies/ml)	Baseline CD4+ Count (cells/cm ³)	Current CD4+ count (cells/cm ³)	Proviral DNA load (copies/10 ⁶ PBMCs)	Years on ART	IL-1ra (pg/ml)	IL-5 (pg/ml)	IL-6 (pg/ml)	IL-10 (pg/ml)	FGF-b (pg/ml)	GM-CSF (pg/ml)	IFN-γ (pg/ml)	VEGF (pg/ml)	sCD14 (pg/ml)	hsCRP (pg/ml)	Composite miRNA score
(a) ART-naïve PLWH																		
NV-62	53	female	55,099	200														
NV-63	46	female	4,716	474														
NV-65	36	female	7,325	310														
NV-66	31	female	12,557	372														
NV-70	24	female	45,837	98														
NV-71	33	male	44,065	288														
NV-72	32	female	549,782	148														
NV-75	32	male	70,268	125														
NV-76	52	female	203,785	NA														
NV-77	47	female	75,536	486														
NV-78	24	female	445,501	533														
NV-79	41	female	14,134	95														
NV-80	40	male	135,581	NA														
NV-83	32	female	47,369	603														
NV-86	19	female	10,175	397														
NV-87	41	male	17,908	299														
(b) ART-treated PLWH																		
SS-09	46	female	ND	160	421	0.2	14	331.7	32.6	0.0	2.0	31.0	0.0	12.4	0.0	11076.0	19900.0	6
SS-16	50	female	ND	189	510	46.6	7	178.7	20.8	0.0	0.9	13.8	0.0	8.9	0.0	12091.0	1550.0	5
SS-17	57	female	ND	70	532	121.2	7	178.7	29.1	0.0	2.0	6.2	0.0	10.7	0.0	9362.9	6990.0	4
SS-20	49	female	ND	NA	495	18064.0	NA	364.0	86.4	0.1	0.9	47.5	10.1	15.4	454.4	9805.2	467.0	6
SS-90	55	female	ND	147	221	2.4	NA	178.7	47.0	0.0	1.5	31.0	0.0	13.8	90.0	9646.1	1110.0	6
SS-91	40	female	ND	140	496	425.0	NA	261.3	110.6	0.5	3.1	26.1	3.6	11.2	192.2	9359.6	741.0	6
SS-94	46	female	ND	NA	675	5470.4	10	297.6	92.6	0.5	2.3	51.1	0.0	19.6	269.7	14653.0	2570.0	6
SS-95	25	male	ND	NA	285	105.3	8	222.0	53.9	0.0	0.9	26.1	0.0	11.2	101.9	15711.0	509.0	5
SS-12	24	male	ND	264	160	0.2	10	480.9	39.9	0.0	3.0	13.8	0.0	38.9	0.0	11168.0	419.0	5
SS-18	45	female	ND	16	564	35.1	14	261.3	47.0	0.0	0.9	23.4	0.0	9.8	0.0	11000.0	233.0	4
SS-19	58	female	ND	222	944	1760.7	8	297.6	17.6	0.0	1.5	31.0	0.0	18.0	0.0	7935.0	1380.0	5
SS-57	51	female	ND	267	478	34.8	14	331.7	60.7	10.1	3.5	23.4	0.0	17.7	0.0	6039.7	7380.0	5
SS-10	54	female	ND	0	1080	5.2	10	297.6	39.9	0.5	1.5	23.4	0.0	13.3	0.0	10256.0	3000.0	4
SS-82	24	male	ND	2	749	0.5	13	331.7	125.2	0.0	2.0	67.3	3.2	23.7	451.6	11264.0	3590.0	3
SS-11	51	male	ND	NA	754	219.7	7	453.2	122.4	3.2	0.9	96.8	14.6	20.0	620.6	8672.9	4630.0	2
SS-14	21	female	ND	NA	425	436.0	9	261.3	53.9	0.0	0.9	13.8	0.0	8.9	0.0	9360.5	104.0	0
SS-15	54	female	263	119	119	0.2	2	178.7	32.6	0.0	2.0	20.5	0.0	10.1	0.0	7589.7	1820.0	0
SS-59	54	female	ND	NA	867	24893.0	7	656.2	122.4	3.2	1.5	70.3	8.5	34.4	628.2	12300.0	13900.0	0
SS-83	43	female	ND	NA	463	468.0	4	279.7	60.7	0.7	2.0	57.9	5.0	28.8	275.9	22196.0	327.0	1
SS-84	47	female	ND	471	605	0.2	2	178.7	47.0	1.2	1.5	43.7	1.8	15.4	263.3	18914.0	1300.0	0
SS-85	53	female	ND	41	399	306.0	9	297.6	98.7	0.0	2.0	61.1	5.9	14.2	459.0	13251.0	14300.0	1
SS-86	22	female	ND	NA	733	0.4	6	222.0	73.8	0.0	0.3	61.1	0.0	10.6	376.9	16056.0	530.0	0
SS-87	54	female	ND	174	707	2.0	NA	222.0	116.5	0.0	0.9	47.5	3.1	9.8	275.9	9371.0	4520.0	0
SS-88	47	female	ND	182	182	0.2	2	222.0	70.5	0.0	0.7	39.8	0.0	11.7	250.3	13014.0	6100.0	2
SS-89	43	female	ND	NA	NA	0.2	NA	364.0	47.0	0.8	2.3	33.3	6.7	19.6	77.0	11373.0	1840.0	1
SS-92	37	female	ND	NA	612	646.3	4	65.3	39.9	0.0	3.9	6.2	0.0	11.2	0.0	12986.0	3150.0	0
SS-93	52	female	ND	NA	239	16.5	NA	222.0	47.0	0.0	0.1	39.8	0.0	8.9	45.3	22647.0	793.0	3
(c) Uninfected controls																		
AGK-P1	34	female																
AGK-P2	39	female																
AGK-P3	48	male																
AGK-P4	32	female																
AGK-P5	24	female																
AGK-P6	29	male																
AGK-P7	26	female																
AGK-P8	22	female																
AGK-P9	40	female																
AGK-P10	29	male																


ND: not detectable (<150copies/ml); NA: not analysed/tested

Supplementary Table 4: Characterization of the isolated extracellular vesicles-preparations from plasma


Participant ID	Nanoparticle tracking analysis (NTA)		Western blot analysis			
	Mode diameter (nm)	Concentration (10 ¹¹ particles/ml)	Protein concentration (ug/ul)	Flotilin-1	Calnexin	Albumin
(a) ART-naïve PLWH						
NV-62	NA	NA	NA	NA	NA	NA
NV-63	NA	NA	NA	NA	NA	NA
NV-65	NA	NA	NA	NA	NA	NA
NV-66	NA	NA	NA	NA	NA	NA
NV-70	NA	NA	NA	NA	NA	NA
NV-71	127.1 ± 1.3	2.81 ± 0.06	1.51	7.30	ND	66.77
NV-72	NA	NA	NA	NA	NA	NA
NV-75	150.8 ± 11.8	0.91 ± 0.03	2.52	1.52	ND	21.87
NV-76	140.9 ± 4.5	2.67 ± 0.11	2.58	0.00	ND	79.88
NV-77	38.4 ± 5.6	0.68 ± 0.22	3.05	0.00	ND	59.73
NV-78	155.6 ± 8.6	0.98 ± 0.04	2.14	9.63	ND	58.56
NV-79	41.8 ± 2.0	1.68 ± 0.05	2.77	31.51	ND	42.10
NV-80	104.7 ± 7.1	1.63 ± 0.07	3.13	28.97	ND	46.05
NV-83	31.1 ± 2.0	0.85 ± 0.07	0.78	5.30	ND	42.08
NV-86	96.0 ± 5.4	1.12 ± 0.05	0.57	11.12	ND	30.57
NV-87	138.6 ± 3.1	1.51 ± 0.09	0.74	9.92	ND	20.87
(b) ART-treated PLWH						
SS-09	126.3 ± 3.1	1.21 ± 0.05	1.73	3.74	ND	74.33
SS-16	152.6 ± 14.3	2.42 ± 0.08	1.51	32.92	ND	54.85
SS-17	134.9 ± 11.3	0.96 ± 0.06	1.18	18.47	ND	48.00
SS-20	135.3 ± 3.7	1.93 ± 0.05	2.29	25.50	ND	57.02
SS-90	133.7 ± 3.9	1.27 ± 0.05	1.89	15.17	ND	16.40
SS-91	145.0 ± 10.7	1.67 ± 0.05	1.22	10.37	ND	26.63
SS-94	120.8 ± 4.2	1.32 ± 0.08	1.23	42.01	ND	19.38
SS-95	146.9 ± 9.4	2.03 ± 0.11	1.62	14.32	ND	16.11
SS-12	131.9 ± 3.2	1.62 ± 0.06	1.20	58.65	ND	84.24
SS-18	135.8 ± 6.6	2.10 ± 0.05	1.78	6.74	ND	48.24
SS-19	84.0 ± 20.3	2.03 ± 0.04	1.74	33.53	ND	64.69
SS-57	121.3 ± 11.4	2.58 ± 0.06	0.94	20.78	ND	57.55
SS-10	22.4 ± 1.1	0.55 ± 0.02	1.27	28.47	ND	44.57
SS-82	108.3 ± 5.9	1.47 ± 0.04	1.13	47.52	ND	57.81
SS-11	94.8 ± 23.9	1.11 ± 0.17	1.66	38.73	ND	79.64
SS-14	128.0 ± 1.7	1.23 ± 0.09	1.07	68.44	ND	88.05
SS-15	122.2 ± 22.9	1.38 ± 0.04	1.26	65.01	ND	57.17
SS-59	136.8 ± 9.2	1.64 ± 0.03	1.55	10.06	ND	43.04
SS-83	105.6 ± 3.7	1.11 ± 0.01	0.83	41.67	ND	37.46
SS-84	111.8 ± 4.8	0.76 ± 0.02	2.19	10.04	ND	41.44
SS-85	64.4 ± 11.0	0.61 ± 0.03	1.38	22.36	ND	32.68
SS-86	120.8 ± 5.3	1.59 ± 0.06	1.39	40.47	ND	31.86
SS-87	131.2 ± 5.2	1.16 ± 0.05	1.53	24.51	ND	31.74
SS-88	142.2 ± 4.8	1.86 ± 0.08	1.32	17.48	ND	30.37
SS-89	136.7 ± 3.7	2.14 ± 0.04	3.85	3.33	ND	25.26
SS-92	101.6 ± 4.3	2.07 ± 0.09	1.34	7.75	ND	21.52
SS-93	117.9 ± 7.3	1.64 ± 0.18	1.26	35.79	ND	21.40
(c) Uninfected controls						
AGK-P1	111.4 ± 8.7	1.63 ± 0.13	0.85	64.34	ND	77.11
AGK-P2	92.9 ± 13.9	1.05 ± 0.09	0.64	34.43	ND	64.04
AGK-P3	134.9 ± 10.2	1.81 ± 0.07	0.92	18.86	ND	52.77
AGK-P4	121.7 ± 7.7	2.64 ± 0.04	0.98	12.59	ND	57.52
AGK-P5	116.3 ± 9.8	1.93 ± 0.08	1.01	13.28	ND	60.90
AGK-P6	114.3 ± 3.4	0.82 ± 0.01	0.67	63.80	ND	33.29
AGK-P7	NA	NA	NA	NA	NA	NA
AGK-P8	117.0 ± 17.4	0.84 ± 0.08	0.94	37.60	ND	44.74
AGK-P9	124.1 ± 6.5	2.28 ± 0.04	0.70	13.07	ND	31.56
AGK-P10	70.2 ± 17.4	0.45 ± 0.05	1.58	11.78	ND	31.13

Mode diameter represents the particle size with maximal occurrence probability. Quantified mode diameters (nm) and particle concentrations (particles/mL), obtained from five technical NTA replicate measurements per sample, are shown as mean ± SEM; ND: no detectable calnexin band observed by western blot; NA: sample unavailable for analysis; Flotillin-1, Calnexin, and Albumin values are presented as percentage relative band intensities referenced to lyophilized HEK293T exosomes, HEK293T cell lysate and plasma supernatant respectively. Uninfected controls (n=9), ART-naïve (n=10), and ART-treated PLWH (n=27).


(a) Flotillin-1 (47-50kDa)



(b) Calnexin (67kDa)



(c) Albumin (65kDa)



Supplementary Figure 1: Western blot analysis of all 46 tested EV-enriched preparations (a) Flotillin-1 referenced against lyophilized HEK293T exosomes, (b) Calnexin referenced against HEK293T cell lysate and (c) Albumin referenced against plasma supernatant in uninfected controls (n=9), ART-naïve (n=10), and ART-treated PLWH (n=27). All lanes were loaded with equal amounts of protein from EV-enriched preparations.